By Jesus Calero

(Reuters) -Danish biotech company Novonesis stuck to its full-year targets on Wednesday, as strong bioenergy demand in India and Latin America helps offset revenue losses caused by negative currency exchange effects, notably from the weak U.S. dollar.

Shares of Novonesis, formed through the merger of Novozymes and Chr. Hansen, were down about 7% at 1140 GMT after it reported second-quarter profit margin below market expectations earlier in the day, hit by currency fluctuations and tariff-related costs.

However, those negative effects were partly offset by local U.S. production, CEO Ester Baiget told Reuters.

Global bioenergy markets are navigating shifting demand and pricing pressures, with some regions hit by inflation and evolving energy policies. In particular, India

See Full Page